Sickle cell disease (SCD) is caused by a point mutation in the β-subunit of hemoglobin. The abnormal hemoglobin polymerizes after releasing oxygen to the tissues, producing long filaments that contort the erythrocyte into a characteristic sickle-shaped conformation. Cardiopulmonary complications, including pulmonary hypertension, diastolic dysfunction, and sudden death (1), are the most common causes of death in SCD. In PNAS, Bakeer et al. (2) delve into the pathobiology of these changes.
The link between sickle hemoglobin and cardiac disease is fairly convoluted. Chronic vascular damage occurs through parallel pathways ( Fig. 1, Left) . Red cells are more rigid, have increased adhesion molecule expression, and become progressively dehydrated, promoting microvascular obstruction. Direct vasoocclusion forms the basis for classic SCD complications, such as dactylitis, pain crisis, osteonecrosis, splenic infarction, and acute chest syndrome.
However, vascular damage in SCD also occurs more insidiously. Red and white blood cell adhesion to vascular endothelia promotes inflammation, and there is a background of recurrent microscopic ischemia-reperfusion injury in many organs (3) . Repeated conformational changes with oxygenation and deoxygenation prematurely age red blood cells, shortening their lifespan 5-to 10-fold, causing anemia and tissue hypoxia. Rapid red cell turnover is partially buffered by increased erythropoiesis. Unfortunately, erythropoiesis is metabolically demanding, and increases procoagulant autophagic vesicles (4) . In addition, developing erythroblasts produce a number of vasoactive signaling molecules, including placental growth factor, that are associated with airway hyperactivity, monocyte activation, and pulmonary hypertension (5) .
Some of the red blood cells escape clearance by the reticuloendothelial system and rupture intravascularly, releasing arginase and erythroid damage-associated molecular pattern molecules, including cell-free hemoglobin (6) . Arginase depletes an important substrate of endothelial nitric oxide synthase, promoting eNOS uncoupling, contributing to decreased nitric oxide bioavailability. In addition, arginase promotes L-ornithine production, favoring smooth muscle cell proliferation and collagen deposition (7) .
Cell-free hemoglobin is also toxic. Circulating haptoglobin binds and clears free hemoglobin efficiently in normal subjects, but this buffering system is overwhelmed in SCD (8) . Free hemoglobin avidly binds nitric oxide and can scavenge NO close to the vessel wall, unlike hemoglobin contained in red blood cells (9) . Acute hemolysis promotes vascular inflammation that can be blocked by nitric oxide donors (10) . In SCD patients, circulating cell-free hemoglobin levels correlate with endothelial reactivity and pulmonary artery pressures (11) .
Circulating free hemoglobin can also be stripped of its protein shell, leaving free heme groups. Heme moities freely participate in redox cycling, causing profound endothelial damage, and can activate the innate immune system through Toll-like receptor 4 (12) . A second buffering protein, hemopexin, is present to remove circulating free heme but is depleted in SCD patients (13) . As a result, micromolar heme injections can produce lethal acute chest syndrome in sickle mice, recapitulating human disease (14) . Hemopexin depletion and heme toxicity are not unique to SCD, but are also critically important in septic shock (15) .
Vaso-occlusive and hemolytic vascular stressors reinforce one another to compound vascular damage. Hence, it is not surprising that all major organs of the body are affected (Fig. 1, Right) . Pulmonary arterial hypertension is caused by pulmonary vascular constriction and increased left ventricular filling pressures, as well as the interaction of both mechanisms (16) . Whereas hemolysis-induced pulmonary arterial hypertension has been relatively well studied, mechanisms for the diastolic dysfunction and sudden death are poorly understood in SCD patients.
In PNAS, Bakeer et al. step firmly into this void (2). Using the Berk mouse model of SCD (a double murine knockout which completely expresses human sickle hemoglobin via a transgene), the authors demonstrate a novel, progressive cardiomyopathy with preserved systolic function, concentric ventricular hypertrophy, impaired diastolic function, left atrial hypertrophy, and a Division of Cardiology, Children's Hospital Los Angeles, Los Angeles, CA 90027
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Myocardial transcriptome analysis demonstrated a marked upregulation of genes associated with extracellular matrix production and angiogenesis. Transcriptome profile also suggested a metabolic shift from glucose to fatty acid metabolism, a change commonly noted in type II diabetes and acute ischemia. CPT1 and CPT2, genes critical for very long-chain fatty acid production and membrane stabilization, were down-regulated. Congenital deficiencies in these genes are associated with hypertrophic cardiomyopathy, diastolic dysfunction, and arrhythmias (17) .
More importantly, Bakeer et al. (2) reproduced the repolarization abnormalities and sudden-death risk that have baffled clinicians for decades. A shocking percentage of SCD patients die from sudden death, despite grossly normal-appearing echocardiograms (1). The Berk mice exhibited both QRS and QT prolongation, consistent with the observed replacement fibrosis. Roughly 40% of their mice died suddenly. Electron microscopy demonstrated chaotic cardiomyocyte remodeling that would explain dispersion in conduction and repolarization velocity. Such islands of impaired electrical conductivity create potential substrates for unstable ventricular tachycardias (Torsades de Pointes). Transcriptome analysis demonstrated decreased expression of SCN4B, AKAP9, CACNA1S, KCNJ2, and SCN4A, which have all been linked to long QT syndromes (18) .
Transcriptome profile also suggested disruptions in circadian rhythm gene expression (SCN, CK1e, Per2, and CLOCK). Abnormal circadian function has been linked to impaired immune function, autonomic nervous system dysfunction, endothelial dysfunction, hypercoagulability, and sudden death (19) . Because all of these complications are common in SCD patients, human studies of circadian rhythm function are warranted.
The cardiac changes in the Berk mouse bear striking similarity to those observed in heart failure with preserved ejection (HFpEF), including concentric hypertrophy, diastolic dysfunction, systolic hypertension, sudden death, microvascular destruction, and a proinflammatory/profibrotic mileau (20) . HFpEF accounts for 50% of heart failure in the general population (20) . Loss of arterial compliance, chronic oxidative stress, systolic hypertension, autonomic system overstimulation, and chronic vascular inflammation play critical roles in both diseases (20) . However, whereas insulin resistance and hyperlipidemia represent the primary vascular stressors in HFpEF, abnormal red cell mechanics and erythroid damage-associated molecular pattern molecules are responsible for chronic vascular inflammation and destruction in SCD. Nonetheless, the two diseases appear to have convergent downstream pathways and may benefit from discoveries in the other arena.
Taken together then, the Bakeer et al. (2) data suggest that the heart suffers from similar progressive microvascular damage as observed in the brain, lungs, liver, and kidneys of SCD patients. Even though global cardiac oxygen delivery may be preserved, loss of capillary cross-sectional area increases oxygen diffusion distances and regional ischemia. Baseline cardiac blood flow is elevated to compensate for anemia, blunting the vasodilatory reserve in response to cardiovascular stress (such as pain crises or acute hemolysis). Greater oxygen extraction increases the risk of vaso-occlusion and further capillary destruction, completing a vicious cycle. Recent cardiac MRI studies suggest that microvascular myocardial infarction is not uncommon in SCD patients during pain crisis and can be easily missed without a high index of suspicion.
Therefore, if we accept this model for cardiac disease in humans with SCD, how might it change our clinical practice? The mainstay of therapy remains the amelioration of the primary hematologic defect, including bone marrow transplantation, chronic transfusion therapy, gene therapy, hydroxyurea, and other hemoglobin F inducers. However, it may be possible to interrupt or at least blunt the vicious cycle of vascular damage by inhibiting extracellular matrix proliferation through manipulations of endothelin/renin/angiotension/aldosterone pathways or modulation of vascular adhesion (e.g., selection blockade). Although the work of Bakeer et al. (2) is a major leap forward, major gaps still exist in the molecular mechanisms linking sickle hemoglobin and the observed cardiac phenotype. However, logical targets already exist. For example, ACE inhibitors blunt the progression of kidney disease in SCD patients. Aldosterone inhibitors are antifibrotic in heart failure and improve diastolic dysfunction in HFpEF (21) . Trials of endothelin blockers are already ongoing (NCT02712346). The importance of blood pressure control, weight management, regular exercise, and correction of sleep disorders can also not be sufficiently emphasized. Fish oil supplementation, statins, and low-dose aspirin therapy all warrant closer investigation. The present work (2) suggests logical outcome variables to evaluate treatment efficacy, including extracellular matrix fraction and myocardial mass by MRI, QTc duration and dispersion by EKG, and diastolic function by echocardiography.
The strongest validation of any experimental model is successful transition to clinical care, but it takes careful experiment design and many patient-years of controlled comparisons to realize these gains. I am cautiously optimistic that the observations of Bakeer et al. (2) will contribute to improved cardiopulmonary protection in SCD patients.
